Diagnostic Test Detects Most Prevalent Sexually Transmitted Diseases

This test should encourage widespread STD screening and help slow the transmission of these infections, thus promoting more responsive and effective patient care.

More than half of all people will be infected with a sexually transmitted disease (STD) at some point in their lifetime. Most STDs are asymptomatic and go undetected. Therefore, less than one-third of these individuals are routinely screened for STDs. Current clinical STD and HPV screening procedures are not cost efficient, as they use a separate test to detect each indication for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Human papillomaviruses (HPV).

STD infections have a high co-infection rate (with afflicted individuals exhibiting more than one STD infection). HPV is the main cause of cervical cancer, and clinical healthcare systems need an effective and economical diagnostic tool, one capable of detecting the most prevalent STD and HPV pathogens with a single test.

Seegene's (Rockville, MD, USA) new Seeplex STD/HPV test screens for CT, NG, 14 high-risk types of HPV, and 5 HPV, low-risk types in a single reaction tube, at the price point of a single pathogen test using the same sample. The new diagnostic test enables healthcare providers to quickly, accurately, and cost-effectively determine most prevalent STD/HPV infections in patients. As a result, physicians will be able to provide the most appropriate course of treatment for their patients.


Related Links:
Seegene